Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltegravir/atazanavir pharmacokinetics and lipid evaluation in virologically suppressed HIV patients
2008-001881-10Phase 3Completed
- Sponsor
- Papa Giovanni XXIII Hospital
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of raltegravir and atazanavir in human immunodeficiency virus infection (HIV), sponsored by Papa Giovanni XXIII Hospital. Primary endpoints: Reduction of lipid abnormalities and Change in need for lipid-lowering therapy. Started Jun 2008; status: completed.
02
Drugs
raltegraviratazanavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2008-001881-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001881-10.